Yohann Loriot

2008–2026 年に発表

207
論文数
49,755
被引用数
77
h 指数
187
i10 指数

被引用数

Yohann Loriot の年別被引用数1945 年: 被引用 1 件1994 年: 被引用 1 件2001 年: 被引用 4 件2005 年: 被引用 1 件2006 年: 被引用 1 件2007 年: 被引用 1 件2009 年: 被引用 8 件2010 年: 被引用 9 件2011 年: 被引用 39 件2012 年: 被引用 68 件2013 年: 被引用 118 件2014 年: 被引用 132 件2015 年: 被引用 263 件2016 年: 被引用 376 件2017 年: 被引用 536 件2018 年: 被引用 738 件2019 年: 被引用 1,931 件2020 年: 被引用 2,514 件2021 年: 被引用 2,711 件2022 年: 被引用 2,331 件2023 年: 被引用 1,945 件2024 年: 被引用 3,360 件2025 年: 被引用 1,736 件2026 年: 被引用 71 件1946〜1993 年は被引用が無いため表示していません1995〜2000 年は被引用が無いため表示していません2002〜2004 年は被引用が無いため表示していません2008 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 5,686 件、この内訳の 23%中国: 引用元論文 3,919 件、この内訳の 15.8%フランス: 引用元論文 1,366 件、この内訳の 5.5%イギリス: 引用元論文 1,319 件、この内訳の 5.3%イタリア: 引用元論文 1,312 件、この内訳の 5.3%ドイツ: 引用元論文 1,123 件、この内訳の 4.6%カナダ: 引用元論文 945 件、この内訳の 3.8%スペイン: 引用元論文 821 件、この内訳の 3.3%日本: 引用元論文 804 件、この内訳の 3.3%オランダ: 引用元論文 689 件、この内訳の 2.8%オーストラリア: 引用元論文 595 件、この内訳の 2.4%スイス: 引用元論文 548 件、この内訳の 2.2%
0%23%その他 22.7%

分野

  • Medicine66.2%
  • Biochemistry, Genetics and Molecular Biology24%
  • Immunology and Microbiology6%
  • Engineering0.9%
  • Computer Science0.4%
  • Health Professions0.4%
  • その他2.1%

トピック

  • Cancer Immunotherapy and Biomarkers12.6%
  • Prostate Cancer Treatment and Research4.5%
  • Gut microbiota and health4.1%
  • Bladder and Urothelial Cancer Treatments4.1%
  • Immunotherapy and Immune Responses3.7%
  • Cancer Genomics and Diagnostics2.8%
  • その他68.2%

共著者

全論文

検索で開く
  1. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Benoît Quinquis, Nicolas Pons, Bernhard Ryffel, Véronique Minard-Colin, Patrick Gonin, Jean‐Charles Soria, Éric Deutsch, Yohann Loriot, François Ghiringhelli, Gérard Zalcman, François Goldwasser, Bernard Escudier, Matthew D. Hellmann, Alexander Eggermont, Didier Raoult, Laurence Albigès, Guido Kroemer, Laurence Zitvogel - Science 2017 被引用: 5,594

  2. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michiel S. van der Heijden, Yohann Loriot, Jonathan E. Rosenberg, Lawrence Fong, Ira Mellman, Daniel S. Chen, Marjorie Green, Christina Louise Derleth, Gregg Fine, Priti S. Hegde, Richard Bourgon, Thomas Powles - Nature 2018 被引用: 5,616

  3. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

    著者: , , , , , , , , , , , , - New England Journal of Medicine 2021 被引用: 1,155

  4. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2024 被引用: 914

  5. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Wolf H. Fridman, François Le Loarer, Antoîne Italiano - Nature Cancer 2021 被引用: 569

  6. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2020 被引用: 1,479

  7. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robert Dreicer - The Lancet 2016 被引用: 3,714

  8. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sanjeev Mariathasan, AnnChristine Thåström, Oyewale O. Abidoye, Gregg Fine, Dean F. Bajorin - The Lancet 2016 被引用: 2,211

  9. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2014 被引用: 3,031

  10. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2019 被引用: 1,365

  11. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

    著者: , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 被引用: 533

  12. Abiraterone and Increased Survival in Metastatic Prostate Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christopher M. Haqq, Howard I. Scher - New England Journal of Medicine 2011 被引用: 4,394

  13. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Brieuc Sautois, Jean‐Pascal Machiels, Denis Schallier, Leandro Brust, Liane Rapatoni, Sérgio Jobim Azevedo, GISELE LOPES MARINHO, João Paulo Holanda Soares, Carlos Dzik, Jamile Almeida Silva, André P. Fay, Joel Gingerich, Yves Fradet, Cristiano Ferrario, Kylea Potvin, Marie Vanhuyse, Mahmoud Abdelsalam, Susanna Cheng, Christian Caglevic, Felipe Reyes, José Luis Leal, Francisco Francisco, Carolina Ibáñez, Florence Joly, Brigitte Laguerre, Sylvain Ladoire, Aude Fléchon, Delphine Topart, Olivier Huillard, Stéphane Oudard, Marine Gross‐Goupil, Stéphane Culine, Yohann Loriot, Gwénaëlle Gravis, Peter Reichardt, Margitta Retz, Jan Herden, David G. Pfister, Carsten Ohlman, Michael Stöeckle, Manfred P. Wirth, Anja Lorch, Guenter Niegisch, Peter J. Goebell, Martin Boegemann, Axel S. Merseburger, Georgios Gakis, Jens Bedke, Andreas Neisius, Christian A. Thomas, Thomas Hoefner, András Telekes, Judit Kósa, János Révész, Gyorgy Bodoky, Tibor Csőszi, András Csejtei, Lajos Géczi, Ágnes Ruzsa, Zsuzsanna Kolonics, József Erfán, Ray McDermott, Richard Bambury, Avishay Sella, Stephen Jay Frank, Daniel Kejzman, Olesya Goldman, Eli Rosenbaum, Avivit Peer, Raanan Berger ほか 158 名 - The Lancet Oncology 2021 被引用: 648

  14. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    著者: , , , , , , , , , , , , - Annals of Oncology 2021 被引用: 525

  15. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma

    著者: , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 被引用: 291

  16. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2017 被引用: 1,416

  17. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

    著者: , , , , , , , , , , , , , , - Nature 2014 被引用: 2,430

  18. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2019 被引用: 597

  19. High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alexander M.M. Eggermont, Fabrice André, Jean‐Charles Soria - Cancer Discovery 2017 被引用: 776

  20. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michiel S. van der Heijden, Andrea Necchi, Daniel Castellano, Aristotelis Bamias, Jae‐Lyun Lee, Ugo De Giorgi, Martin Bögemann, Bernhard J. Eigl, Marinos Tsiatas, Thomas Powles, Andrey Novikov, Iwona Skoneczna, Som D. Mukherjee, Cristina Suárez, Hans M. Westgeest, Yves Fradet, Aude Fléchon, Yen‐Chuan Ou, Inkeun Park, Vsevolod Matveev, Begoña Pérez‐Valderrama, Susanna Cheng, Stephen Jay Frank, Howard Gurney, Urbano Anido, Alketa Hamzaj, Margitta Retz, Srikala S. Sridhar, Giorgio V. Scagliotti, Jens Voortman, B. Yа. Alekseev, Anna Alyasova, B. K. Komyakov, Herlinde Dumez, Michel Pavic, Go Kimura, Atsushi Mizokami, Susanne Osanto, José Ángel Arranz, Djura Piersma, Sang Joon Shin, O. B. Karyakin, Ignacio Delgado, José Luis González, See‐Tong Pang, Anna Tran, Oleg Lipatov, Wen-Pin Su, Thomas W. Flaig, Ajjai Alva, Hwa Park Kyong, Evgeny Kopyltsov, Elena Almagro, M. Doménech, Yen‐Hwa Chang, Brieuc Sautois, Andre Ravaux, Gerasimos Aravantinos, V. Georgoulias, Sasja F. Mulder, Yu Jung Kim, Fabio Kater, Christine Chevreau, Scott T. Tagawa, Paweł Zalewski, Florence Joly, Yohann Loriot, Gencay Hatiboglu, Luca Gianni, Franco Morelli ほか 127 名 - The Lancet Oncology 2020 被引用: 498

  21. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alison Y. Zhang, Hans Prenen, Jean‐Charles Goeminne, Jean‐Pascal Machiels, Sylvie Rottey, Marcelo Corassa, Graziela Zibetti Dal Molin, Katsuki Arima Tiscoski, Denis L. Jardim, Milena Perez Mak, Wei Fu, Herui Yao, Jing Huang, Haiping Jiang, Jing Huang, Baoshi Chen, Dong Yan, Yu Yang, Yohann Loriot, Christophe Le Tourneau, Nicolas Penel, Sébastien Salas, Jean‐Yves Blay, Pierre-Emmanuel Brachet, Xavier Durando, Sheik Emambux, Alain Ravaud, Gunnar Folprecht, Dirk Arnold, Martin Schüler, Marit Ahrens, Alexander Golf, Georg Martin Haag, Florian Lordick, Alexander Desuki, Marina Elena Cazzaniga, Fortunato Ciardiello, Michèle Milella, Takafumi Koyama, Yoshiki Hirooka, Wataru Okamoto, Kenjiro Aogi, Yasutoshi Kuboki, Jung-Yun Lee, Sung‐Bae Kim, Myung‐Ju Ahn, Jong Hee Chang, Yongman Kim, Do‐Hyun Nam, Jaesung Park, Iwona Ługowska, Luis Paz‐Ares, Víctor Moreno, Andrés Cervantes, Mariona Calvo, Alejandro Falcón, Antonio González, Josep Tabernero, A. Martinez Bueno, Javier García-Corbacho, Federico Longo, Chia‐Jui Yen, Jen‐Shi Chen, Ming‐Feng Hou, Yee Chao, Kun‐Ming Rau, Tai‐Jan Chiu, Yin‐Hsun Feng, Chih‐Hung Hsu, Wen‐Tsung Huang ほか 33 名 - The Lancet Oncology 2023 被引用: 200

  22. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 被引用: 267

  23. Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up

    著者: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 被引用: 211

  24. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma

    著者: , , , , , , , , , , , , , - Annals of Oncology 2023 被引用: 153